

As part of that review, the online survey will be used to:
Measure the effect of the 2016–2017 HIPAA Audits on covered entities’ and business associates’ subsequent actions to comply with the HIPAA Rules.
Provide entities with an opportunity to give feedback on the Audit and its features, such as the helpfulness of

HHS’ guidance materials and communications, the utility of the online submission portal, whether the Audit helped improve entity compliance, and the entities’ responses to the Audit-report findings and recommendations.
Provide OCR with information on the burden imposed on entities to collect

audit-related documents and to respond to audit-related requests; and
Seek feedback on the effect of the HIPAA Audit program on the entities’ day-to-day business operations.
The information, opinions, and comments collected using the online survey will be used to improve future OCR HIPAA Audits.

ANNUALIZED BURDEN HOUR TABLE

Form name	Respondents	Number of respondents	Number of responses per respondent	Average burden per response	Total burden hours
OCR HIPAA Audit Participant Survey.	Covered Entity Privacy and Security Officer(s) or Administrators.	166	1	45/60	124.5
OCR HIPAA Audit Participant Survey.	Business Associate Privacy and Security Officer(s) or Administrators.	41	1	45/60	30.75
Total	207	155.25

Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.
[FR Doc. 2024–02737 Filed 2–9–24; 8:45 am]
BILLING CODE 4153–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Maximizing Investigators’ Research Award—E Study Section, March 05, 2024, 8 a.m. to March 6, 2024, 6 p.m., Center for Scientific Review, RKL2, 6701 Rockledge Dr, Bethesda, MD, 20817 which was published in the **Federal Register** on February 06, 2024, 89 FR 8218, Doc 2024–02265.

This meeting is being amended to change the meeting start time from 8 a.m. to 9 a.m. The meeting is closed to the public.

Dated: February 6, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024–02775 Filed 2–9–24; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required).

Date: March 8, 2024.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Video Assisted Meeting).

Contact Person: Lindsey M. Pujanandez, Ph.D., Scientific Review Officer, Immunology Review Branch, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, MSC 9834, Rockville, MD 20852, (240) 627–3206, *lindsey.pujanandez@nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: February 6, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024–02773 Filed 2–9–24; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; URGENT: Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders.

Date: February 27, 2024.
Time: 10:00 a.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6001 Executive Boulevard, Rockville, MD 20852.

Contact Person: Mirela Milescu, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, NINDS/NIH, HHS NSC, 6001 Executive Blvd., Rockville, MD 20852, 301-496-5720, mirela.milescu@nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS.)

Dated: February 6, 2024.

Lauren A. Fleck,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-02774 Filed 2-9-24; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY

U.S. Customs and Border Protection

Extension and Modification of the National Customs Automation Program Test Concerning the Submission Through the Automated Commercial Environment of Certain Unique Entity Identifiers for the Global Business Identifier Evaluative Proof of Concept

AGENCY: U.S. Customs and Border Protection, Department of Homeland Security.

ACTION: General notice.

SUMMARY: On July 21, 2023, U.S. Customs and Border Protection (CBP) published a notice in the **Federal Register** extending and modifying a National Customs Automation Program Test concerning the submission of unique entity identifiers for the Global Business Identifier (GBI) Evaluative Proof of Concept (EPoC). This document republishes and supersedes the notice published on July 21, 2023, announces an extension of the test period through February 23, 2027, notes a clarification in the purpose and scope of the GBI EPoC, and removes commodity and country of origin limitations on the entries eligible for the test. In addition, this document makes changes to the contact information for questions regarding the test, provides new web addresses dedicated to obtaining GBIs, and makes minor technical changes.

DATES: The GBI EPoC commenced on December 19, 2022, and will continue through February 23, 2027, subject to any extension, modification, or early termination as announced in the **Federal Register**. CBP began to accept requests from importers of record and licensed customs brokers to participate in the test on December 2, 2022, and CBP will continue to accept such requests until the GBI EPoC concludes. Public comments on the test are invited and may be submitted to the address set forth below, at any time during the test period.

FOR FURTHER INFORMATION CONTACT: For policy-related questions, contact Garrett Wright, Director, Trade Modernization Division, Trade Policy and Programs Directorate, Office of Trade, U.S. Customs and Border Protection, at (202) 897-9877 or via email at GBI@cbp.dhs.gov, with a subject line reading “Global Business Identifier Test-GBI.” For technical questions related to the Automated Commercial Environment (ACE) or Automated Broker Interface (ABI) transmissions, software vendors, importers of record, and licensed customs brokers should contact their assigned ACE or ABI client representatives, respectively. Interested parties without an assigned client representative should direct their questions to Steven Zaccaro, Client Services Division, Office of Trade, U.S. Customs and Border Protection, at (571) 358-7809 or via email at clientreputreach@cbp.dhs.gov.

SUPPLEMENTARY INFORMATION: On December 2, 2022, U.S. Customs and Border Protection (CBP) published a General Notice (the December 2 Notice) in the **Federal Register** (87 FR 74157) announcing a National Customs Automation Program (NCAP) Test concerning the submission through the Automated Commercial Environment (ACE) of certain unique entity identifiers for the Global Business Identifier (GBI) Evaluative Proof of Concept (EPoC). On July 21, 2023, CBP published a General Notice (the July 21 Notice) in the **Federal Register** (88 FR 47154) extending and modifying the December 2 Notice. Specifically, the July 21 Notice extended the test period from July 21, 2023, through February 14, 2024; provided the correct web address for interested parties to use to obtain the Legal Entity Identifier (LEI) from the Global Legal Entity Identifier Foundation (GLEIF); and clarified that CBP would allow participants to provide one or more of the three identifiers for the manufacturers, shippers, and sellers (and optionally, exporters, distributors, and packagers)

of merchandise, and that CBP would not require transmission of all three identifiers to participate in the test. This document republishes and supersedes the July 21 Notice, with the following modifications.

First, the test period has been extended from February 14, 2024, through February 23, 2027. Second, CBP made changes to Sections I.B. (Global Business Identifier Evaluative Proof of Concept (GBI EPoC)) and VI. (Evaluation Criteria) to clarify the purpose and scope of the test. CBP will continue to assess the functionality and effectiveness of universal global business identifiers to address data gaps caused by the unreliability of the manufacturer or shipper identification code (MID), in addition to exploring opportunities to enhance supply chain traceability and visibility more broadly—including examining how CBP, Partner Government Agencies (PGAs), and the trade industry might leverage GBIs to comply with growing supply chain traceability requirements.

Third, CBP has expanded the GBI EPoC to include entries of merchandise classifiable in any subheading of the Harmonized Tariff Schedule of the United States (HTSUS) and entries of imported merchandise from any country of origin. When CBP initially launched the GBI EPoC, the test was limited to entries of merchandise in five (5) categories (alcohol, toys, seafood, personal items, and medical devices), and to merchandise with 10 countries of origin (Australia, Canada, China, France, Italy, Mexico, New Zealand, Singapore, United Kingdom, and Vietnam). These requirements significantly limited the range of entries that could be evaluated under the test. As a result, CBP is removing these test limitations. It is important to note that the test continues to be limited to type 01 (formal) and type 11 (informal) entries.

Fourth, as noted in the **FOR FURTHER INFORMATION CONTACT** section above, the office responsible for the GBI EPoC has changed (it is no longer the Interagency Collaboration Division, Trade Policy and Programs Directorate, Office of Trade, but is now the Trade Modernization Division, Trade Policy and Programs Directorate, Office of Trade), and the point of contact for interested parties without an assigned client representative who have technical questions has changed. Fifth, GS1 and Dun & Bradstreet have created specific web pages dedicated to the GBI EPoC for obtaining a GBI; Section III.A. (Obtaining Global Business Identifier (GBI) Numbers) has been updated to include the new web addresses for the